Results 221 to 230 of about 47,221 (287)

Case Report: Pathologic complete response in triple negative breast cancer treated with anthracycline free regimen. [PDF]

Front Oncol
Piazza F, Scartabellati G, Moretti L, Laganà M, Vassalli L, Trevisan B, Bazzoli M, Schivardi G, Canzi F, Baraziol R, Ippolito G, Grisanti S, Berruti A, Cosentini D, Pedersini R.   +14 more
europepmc   +1 more source

Manipulating anthracyclines for deeper tissue penetration and implications for glycolytic tissues. [PDF]

Proc Natl Acad Sci U S A
Abels ER, Ter Linden E, Rohling JHT, Voortman LM, Janssen L, Hornsveld M, Overkleeft HS, van der Zanden SY, Broekman MLD, Neefjes J.   +9 more
europepmc   +1 more source

Angiotensin converting enzyme inhibitors (ACEIs) for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Saudi Med
Safwan M, Bourgleh MS, AlShakaki H, Haider KH.   +3 more
europepmc   +1 more source

Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma-A Regression Analysis of Dose-Response. [PDF]

Hematol Oncol
Nygård L, Vogelius IR, Kofoed KF, Bentzen S, Specht L.   +4 more
europepmc   +1 more source

Pharmacogenomic predictors of anthracycline-induced cardiotoxicity in breast cancer patients: a systematic review and meta-analysis. [PDF]

Cardiooncology
Bulusu VM, Shah B, Sawant S, Choudhary A, Das S, Jain S, Mallayasamy SR, Udupa KS, Arya N, Singh J, Rao M, Kanwar RK, Kumar A, Munisamy M.   +13 more
europepmc   +1 more source

Heartbreakers and healers: RNA rebels in cardio-oncology. [PDF]

Semin Cancer Biol
Agyemang-Dua C, Chung CS, Espinosa-Diez C.   +2 more
europepmc   +1 more source

Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer. [PDF]

Ann Oncol
Chen N, Freeman JQ, Yarlagadda S, Atmakuri A, Kalinsky K, Pusztai L, Sparano JA, Huo D, Nanda R, Howard FM.   +9 more
europepmc   +1 more source

Reply: Trastuzumab Cardiotoxicity: No Need for Ejection Fraction Monitoring Without Prior Anthracycline Exposure. [PDF]

JACC CardioOncol
Ali A, Deswal A.
europepmc   +1 more source

Oncologic Outcomes and Safety of Neoadjuvant Treatment with Anthracyclines Versus Anthracycline-Free Regimens in HER2-Positive Early Breast Cancer in a Colombian Cancer Center: An Observational, Analytical, Retrospective Study. [PDF]

Cancers (Basel)
Acevedo-Ramos A, Zuluaga-Liberato A, Díaz-Casas SE.   +2 more
europepmc   +1 more source

Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens. [PDF]

Cureus
Bonsu A.
europepmc   +1 more source